Forecast
The analysts' average price target is €37.98 (-10.42%). The median is €35.54 (-16.18%).
| Buy |
Â
7 |
| Hold |
Â
13 |
| Sell |
Â
1 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
CONMED: growth accelerates due to AirSeal, BioBrace and international expansion
CONMED reports at the Wells Fargo conference an accelerated growth dynamic and expects 2026 revenue growth of 5–6% with a pickup to 6–8% in the second half of the year. Drivers are the products AirSeal, BioBrace and Buffalo Filter as well as increasing internationalization, which now accounts for 45% of revenue. Management sees margin expansion of 50–100 basis points, improved free cash flow conversion through inventory and working-capital optimization, and plans selective acquisitions while prioritizing debt reduction. » More on de.investing.com
CONMED Corporation considers sale – shares jump more than 8% after Bloomberg report
CONMED Corporation’s shares rose more than 8 percent in Friday after-hours trading after Bloomberg reported that the medical-technology company was weighing a possible sale. According to the report, CONMED is evaluating its options after takeover interest was expressed. » More on de.investing.com
CONMED appoints John E. Gallagher as CFO effective July 15, 2026
CONMED has appointed John E. Gallagher as its new chief financial officer; he will assume the role on July 15, 2026. Gallagher succeeds Todd Garner, who will remain with the company in an advisory capacity until November 2, 2026. Gallagher brings about 30 years of financial and industry experience, most recently as CFO of Certara and previously of Cue Health, along with extensive leadership experience at Becton, Dickinson & Co. » More on de.investing.com
Conmed stock falls to 52-week low at $32.1
Conmed shares hit a 52-week low of $32.1 and are down about 37.92% year-to-date. Despite the price decline, the company is rated as having a "GOOD" financial score and is valued at a P/E ratio of 18.27; InvestingPro classifies the stock as significantly undervalued. Conmed beat Q1 2026 analyst expectations for EPS ($0.89 vs. $0.82) and revenue ($317 million) and secured a $450 million term-loan facility to repay convertible bonds. Management repurchased shares, and the board will be expanded on July 1, 2026, with the additions of Celine Martin and Jeff Mirviss. » More on de.investing.com
CONMED raises organic growth, gastroenterology exit weighs on revenue
CONMED beat adjusted EPS expectations for Q1 2026 with $0.89 and reported total revenue of $317.0 million, with reported growth pressured by the withdrawal from the gastroenterology business and currency effects. Adjusted for the divestiture of the GI business, organic growth at constant exchange rates was 2.1%, while the divestiture caused a 5.1 percentage-point headwind. Orthopedic surgery showed strong momentum with $147.7 million and +4.5% currency‑adjusted growth, while domestic revenue declined. CONMED raised its organic full-year growth outlook to 5.0–6.5%, kept the adjusted EPS target at $4.30–4.45, and emphasized portfolio focus and supply‑chain transformation; the stock nevertheless fell in after‑hours trading. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsIn 2025, CONMED Co. has already paid €0.71 in dividends. The last payout was in October 2025.
Financials
In the last quarter, CONMED Co. had revenue of €296.25M and net profit of €17.48M
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 296.25M | 2.68% |
| Gross profit | 166.99M | 24.06% |
| Net profit | 17.48M | 617.37% |
| EBITDA | 49.73M | 91.42% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.26B |
Number of shares | 29.8M |
52-week high/low | €49.94 - €28.65 |
| Dividends | No |
Beta | 0.90 |
P/E ratio | 19.24 |
PEG ratio | 1.10 |
P/B ratio | 1.31 |
P/S ratio | 1.01 |
Company profile
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
| Name | CONMED Co. |
| CEO | Patrick J. Beyer |
| Headquarters | Largo,
fl USA |
| Website | |
| Sector | Health Care |
| Industry | Health Care Technology |
| IPO | 07/23/1987 |
| Employees | 3,900 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | CNMD |
Frankfurt | EC8.F |
DĂĽsseldorf | EC8.DU |
SIX | EC8.SW |
MĂĽnchen | EC8.MU |